Global Myelodysplastic Syndrome Market Research Report 2023

The global Myelodysplastic Syndrome market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

North American market for Myelodysplastic Syndrome is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.

Asia-Pacific market for Myelodysplastic Syndrome is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.

The global market for Myelodysplastic Syndrome in Hospital is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.

The key global companies of Myelodysplastic Syndrome include Celgene, Novartis, Otsuka, Actinium Pharmaceuticals, Acceleron Pharma, Bellicum Pharmaceuticals, Cornerstone Pharmaceuticals, CTI BioPharma and Onconova Therapeutics, etc. In 2022, the world's top three vendors accounted for approximately % of the revenue.

This report aims to provide a comprehensive presentation of the global market for Myelodysplastic Syndrome, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Myelodysplastic Syndrome.

The Myelodysplastic Syndrome market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Myelodysplastic Syndrome market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Myelodysplastic Syndrome companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Myelodysplastic Syndrome Market Size Growth Rate by Type: 2018 VS 2022 VS 2029

1.2.2 Alkylating Agents

1.2.3 Cytotoxic Antibiotics

1.2.4 Topoisomerase Inhibitors

1.2.5 Others

1.3 Market by Application

1.3.1 Global Myelodysplastic Syndrome Market Growth by Application: 2018 VS 2022 VS 2029

1.3.2 Hospital

1.3.3 Clinic

1.4 Study Objectives

1.5 Years Considered

1.6 Years Considered

2.1 Global Myelodysplastic Syndrome Market Perspective (2018-2029)

2.2 Myelodysplastic Syndrome Growth Trends by Region

2.2.1 Global Myelodysplastic Syndrome Market Size by Region: 2018 VS 2022 VS 2029

2.2.2 Myelodysplastic Syndrome Historic Market Size by Region (2018-2023)

2.2.3 Myelodysplastic Syndrome Forecasted Market Size by Region (2024-2029)

2.3 Myelodysplastic Syndrome Market Dynamics

2.3.1 Myelodysplastic Syndrome Industry Trends

2.3.2 Myelodysplastic Syndrome Market Drivers

2.3.3 Myelodysplastic Syndrome Market Challenges

2.3.4 Myelodysplastic Syndrome Market Restraints

3.1 Global Top Myelodysplastic Syndrome Players by Revenue

3.1.1 Global Top Myelodysplastic Syndrome Players by Revenue (2018-2023)

3.1.2 Global Myelodysplastic Syndrome Revenue Market Share by Players (2018-2023)

3.2 Global Myelodysplastic Syndrome Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Players Covered: Ranking by Myelodysplastic Syndrome Revenue

3.4 Global Myelodysplastic Syndrome Market Concentration Ratio

3.4.1 Global Myelodysplastic Syndrome Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Myelodysplastic Syndrome Revenue in 2022

3.5 Myelodysplastic Syndrome Key Players Head office and Area Served

3.6 Key Players Myelodysplastic Syndrome Product Solution and Service

3.7 Date of Enter into Myelodysplastic Syndrome Market

3.8 Mergers & Acquisitions, Expansion Plans

4.1 Global Myelodysplastic Syndrome Historic Market Size by Type (2018-2023)

4.2 Global Myelodysplastic Syndrome Forecasted Market Size by Type (2024-2029)

5.1 Global Myelodysplastic Syndrome Historic Market Size by Application (2018-2023)

5.2 Global Myelodysplastic Syndrome Forecasted Market Size by Application (2024-2029)

6.1 North America Myelodysplastic Syndrome Market Size (2018-2029)

6.2 North America Myelodysplastic Syndrome Market Growth Rate by Country: 2018 VS 2022 VS 2029

6.3 North America Myelodysplastic Syndrome Market Size by Country (2018-2023)

6.4 North America Myelodysplastic Syndrome Market Size by Country (2024-2029)

6.5 United States

6.6 Canada

7.1 Europe Myelodysplastic Syndrome Market Size (2018-2029)

7.2 Europe Myelodysplastic Syndrome Market Growth Rate by Country: 2018 VS 2022 VS 2029

7.3 Europe Myelodysplastic Syndrome Market Size by Country (2018-2023)

7.4 Europe Myelodysplastic Syndrome Market Size by Country (2024-2029)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8.1 Asia-Pacific Myelodysplastic Syndrome Market Size (2018-2029)

8.2 Asia-Pacific Myelodysplastic Syndrome Market Growth Rate by Region: 2018 VS 2022 VS 2029

8.3 Asia-Pacific Myelodysplastic Syndrome Market Size by Region (2018-2023)

8.4 Asia-Pacific Myelodysplastic Syndrome Market Size by Region (2024-2029)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9.1 Latin America Myelodysplastic Syndrome Market Size (2018-2029)

9.2 Latin America Myelodysplastic Syndrome Market Growth Rate by Country: 2018 VS 2022 VS 2029

9.3 Latin America Myelodysplastic Syndrome Market Size by Country (2018-2023)

9.4 Latin America Myelodysplastic Syndrome Market Size by Country (2024-2029)

9.5 Mexico

9.6 Brazil

10.1 Middle East & Africa Myelodysplastic Syndrome Market Size (2018-2029)

10.2 Middle East & Africa Myelodysplastic Syndrome Market Growth Rate by Country: 2018 VS 2022 VS 2029

10.3 Middle East & Africa Myelodysplastic Syndrome Market Size by Country (2018-2023)

10.4 Middle East & Africa Myelodysplastic Syndrome Market Size by Country (2024-2029)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11.1 Celgene

11.1.1 Celgene Company Detail

11.1.2 Celgene Business Overview

11.1.3 Celgene Myelodysplastic Syndrome Introduction

11.1.4 Celgene Revenue in Myelodysplastic Syndrome Business (2018-2023)

11.1.5 Celgene Recent Development

11.2 Novartis

11.2.1 Novartis Company Detail

11.2.2 Novartis Business Overview

11.2.3 Novartis Myelodysplastic Syndrome Introduction

11.2.4 Novartis Revenue in Myelodysplastic Syndrome Business (2018-2023)

11.2.5 Novartis Recent Development

11.3 Otsuka

11.3.1 Otsuka Company Detail

11.3.2 Otsuka Business Overview

11.3.3 Otsuka Myelodysplastic Syndrome Introduction

11.3.4 Otsuka Revenue in Myelodysplastic Syndrome Business (2018-2023)

11.3.5 Otsuka Recent Development

11.4 Actinium Pharmaceuticals

11.4.1 Actinium Pharmaceuticals Company Detail

11.4.2 Actinium Pharmaceuticals Business Overview

11.4.3 Actinium Pharmaceuticals Myelodysplastic Syndrome Introduction

11.4.4 Actinium Pharmaceuticals Revenue in Myelodysplastic Syndrome Business (2018-2023)

11.4.5 Actinium Pharmaceuticals Recent Development

11.5 Acceleron Pharma

11.5.1 Acceleron Pharma Company Detail

11.5.2 Acceleron Pharma Business Overview

11.5.3 Acceleron Pharma Myelodysplastic Syndrome Introduction

11.5.4 Acceleron Pharma Revenue in Myelodysplastic Syndrome Business (2018-2023)

11.5.5 Acceleron Pharma Recent Development

11.6 Bellicum Pharmaceuticals

11.6.1 Bellicum Pharmaceuticals Company Detail

11.6.2 Bellicum Pharmaceuticals Business Overview

11.6.3 Bellicum Pharmaceuticals Myelodysplastic Syndrome Introduction

11.6.4 Bellicum Pharmaceuticals Revenue in Myelodysplastic Syndrome Business (2018-2023)

11.6.5 Bellicum Pharmaceuticals Recent Development

11.7 Cornerstone Pharmaceuticals

11.7.1 Cornerstone Pharmaceuticals Company Detail

11.7.2 Cornerstone Pharmaceuticals Business Overview

11.7.3 Cornerstone Pharmaceuticals Myelodysplastic Syndrome Introduction

11.7.4 Cornerstone Pharmaceuticals Revenue in Myelodysplastic Syndrome Business (2018-2023)

11.7.5 Cornerstone Pharmaceuticals Recent Development

11.8 CTI BioPharma

11.8.1 CTI BioPharma Company Detail

11.8.2 CTI BioPharma Business Overview

11.8.3 CTI BioPharma Myelodysplastic Syndrome Introduction

11.8.4 CTI BioPharma Revenue in Myelodysplastic Syndrome Business (2018-2023)

11.8.5 CTI BioPharma Recent Development

11.9 Onconova Therapeutics

11.9.1 Onconova Therapeutics Company Detail

11.9.2 Onconova Therapeutics Business Overview

11.9.3 Onconova Therapeutics Myelodysplastic Syndrome Introduction

11.9.4 Onconova Therapeutics Revenue in Myelodysplastic Syndrome Business (2018-2023)

11.9.5 Onconova Therapeutics Recent Development

11.10 Strategia Therapeutics

11.10.1 Strategia Therapeutics Company Detail

11.10.2 Strategia Therapeutics Business Overview

11.10.3 Strategia Therapeutics Myelodysplastic Syndrome Introduction

11.10.4 Strategia Therapeutics Revenue in Myelodysplastic Syndrome Business (2018-2023)

11.10.5 Strategia Therapeutics Recent Development

11.11 KaloBios Pharmaceuticals

11.11.1 KaloBios Pharmaceuticals Company Detail

11.11.2 KaloBios Pharmaceuticals Business Overview

11.11.3 KaloBios Pharmaceuticals Myelodysplastic Syndrome Introduction

11.11.4 KaloBios Pharmaceuticals Revenue in Myelodysplastic Syndrome Business (2018-2023)

11.11.5 KaloBios Pharmaceuticals Recent Development

11.12 Kiadis Pharma

11.12.1 Kiadis Pharma Company Detail

11.12.2 Kiadis Pharma Business Overview

11.12.3 Kiadis Pharma Myelodysplastic Syndrome Introduction

11.12.4 Kiadis Pharma Revenue in Myelodysplastic Syndrome Business (2018-2023)

11.12.5 Kiadis Pharma Recent Development

11.13 Mirati Therapeutics

11.13.1 Mirati Therapeutics Company Detail

11.13.2 Mirati Therapeutics Business Overview

11.13.3 Mirati Therapeutics Myelodysplastic Syndrome Introduction

11.13.4 Mirati Therapeutics Revenue in Myelodysplastic Syndrome Business (2018-2023)

11.13.5 Mirati Therapeutics Recent Development

11.14 Astex

11.14.1 Astex Company Detail

11.14.2 Astex Business Overview

11.14.3 Astex Myelodysplastic Syndrome Introduction

11.14.4 Astex Revenue in Myelodysplastic Syndrome Business (2018-2023)

11.14.5 Astex Recent Development

11.15 Celator Pharmaceuticals

11.15.1 Celator Pharmaceuticals Company Detail

11.15.2 Celator Pharmaceuticals Business Overview

11.15.3 Celator Pharmaceuticals Myelodysplastic Syndrome Introduction

11.15.4 Celator Pharmaceuticals Revenue in Myelodysplastic Syndrome Business (2018-2023)

11.15.5 Celator Pharmaceuticals Recent Development

11.16 Eli-lilly

11.16.1 Eli-lilly Company Detail

11.16.2 Eli-lilly Business Overview

11.16.3 Eli-lilly Myelodysplastic Syndrome Introduction

11.16.4 Eli-lilly Revenue in Myelodysplastic Syndrome Business (2018-2023)

11.16.5 Eli-lilly Recent Development

11.17 Sunesis Pharmaceuticals

11.17.1 Sunesis Pharmaceuticals Company Detail

11.17.2 Sunesis Pharmaceuticals Business Overview

11.17.3 Sunesis Pharmaceuticals Myelodysplastic Syndrome Introduction

11.17.4 Sunesis Pharmaceuticals Revenue in Myelodysplastic Syndrome Business (2018-2023)

11.17.5 Sunesis Pharmaceuticals Recent Development

11.18 Targazyme

11.18.1 Targazyme Company Detail

11.18.2 Targazyme Business Overview

11.18.3 Targazyme Myelodysplastic Syndrome Introduction

11.18.4 Targazyme Revenue in Myelodysplastic Syndrome Business (2018-2023)

11.18.5 Targazyme Recent Development

11.19 Gamida Cell

11.19.1 Gamida Cell Company Detail

11.19.2 Gamida Cell Business Overview

11.19.3 Gamida Cell Myelodysplastic Syndrome Introduction

11.19.4 Gamida Cell Revenue in Myelodysplastic Syndrome Business (2018-2023)

11.19.5 Gamida Cell Recent Development

11.20 GlaxoSmithKline

11.20.1 GlaxoSmithKline Company Detail

11.20.2 GlaxoSmithKline Business Overview

11.20.3 GlaxoSmithKline Myelodysplastic Syndrome Introduction

11.20.4 GlaxoSmithKline Revenue in Myelodysplastic Syndrome Business (2018-2023)

11.20.5 GlaxoSmithKline Recent Development

11.21 Sumitomo Dainippon Pharma

11.21.1 Sumitomo Dainippon Pharma Company Detail

11.21.2 Sumitomo Dainippon Pharma Business Overview

11.21.3 Sumitomo Dainippon Pharma Myelodysplastic Syndrome Introduction

11.21.4 Sumitomo Dainippon Pharma Revenue in Myelodysplastic Syndrome Business (2018-2023)

11.21.5 Sumitomo Dainippon Pharma Recent Development

11.22 TetraLogic Pharmaceuticals

11.22.1 TetraLogic Pharmaceuticals Company Detail

11.22.2 TetraLogic Pharmaceuticals Business Overview

11.22.3 TetraLogic Pharmaceuticals Myelodysplastic Syndrome Introduction

11.22.4 TetraLogic Pharmaceuticals Revenue in Myelodysplastic Syndrome Business (2018-2023)

11.22.5 TetraLogic Pharmaceuticals Recent Development

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.2 Data Source

13.2 Disclaimer

13.3 Author Details

List of Tables

    Table 1. Global Myelodysplastic Syndrome Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2029

    Table 2. Key Players of Alkylating Agents

    Table 3. Key Players of Cytotoxic Antibiotics

    Table 4. Key Players of Topoisomerase Inhibitors

    Table 5. Key Players of Others

    Table 6. Global Myelodysplastic Syndrome Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2029

    Table 7. Global Myelodysplastic Syndrome Market Size by Region (US$ Million): 2018 VS 2022 VS 2029

    Table 8. Global Myelodysplastic Syndrome Market Size by Region (2018-2023) & (US$ Million)

    Table 9. Global Myelodysplastic Syndrome Market Share by Region (2018-2023)

    Table 10. Global Myelodysplastic Syndrome Forecasted Market Size by Region (2024-2029) & (US$ Million)

    Table 11. Global Myelodysplastic Syndrome Market Share by Region (2024-2029)

    Table 12. Myelodysplastic Syndrome Market Trends

    Table 13. Myelodysplastic Syndrome Market Drivers

    Table 14. Myelodysplastic Syndrome Market Challenges

    Table 15. Myelodysplastic Syndrome Market Restraints

    Table 16. Global Myelodysplastic Syndrome Revenue by Players (2018-2023) & (US$ Million)

    Table 17. Global Myelodysplastic Syndrome Market Share by Players (2018-2023)

    Table 18. Global Top Myelodysplastic Syndrome Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Myelodysplastic Syndrome as of 2022)

    Table 19. Ranking of Global Top Myelodysplastic Syndrome Companies by Revenue (US$ Million) in 2022

    Table 20. Global 5 Largest Players Market Share by Myelodysplastic Syndrome Revenue (CR5 and HHI) & (2018-2023)

    Table 21. Key Players Headquarters and Area Served

    Table 22. Key Players Myelodysplastic Syndrome Product Solution and Service

    Table 23. Date of Enter into Myelodysplastic Syndrome Market

    Table 24. Mergers & Acquisitions, Expansion Plans

    Table 25. Global Myelodysplastic Syndrome Market Size by Type (2018-2023) & (US$ Million)

    Table 26. Global Myelodysplastic Syndrome Revenue Market Share by Type (2018-2023)

    Table 27. Global Myelodysplastic Syndrome Forecasted Market Size by Type (2024-2029) & (US$ Million)

    Table 28. Global Myelodysplastic Syndrome Revenue Market Share by Type (2024-2029)

    Table 29. Global Myelodysplastic Syndrome Market Size by Application (2018-2023) & (US$ Million)

    Table 30. Global Myelodysplastic Syndrome Revenue Market Share by Application (2018-2023)

    Table 31. Global Myelodysplastic Syndrome Forecasted Market Size by Application (2024-2029) & (US$ Million)

    Table 32. Global Myelodysplastic Syndrome Revenue Market Share by Application (2024-2029)

    Table 33. North America Myelodysplastic Syndrome Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029

    Table 34. North America Myelodysplastic Syndrome Market Size by Country (2018-2023) & (US$ Million)

    Table 35. North America Myelodysplastic Syndrome Market Size by Country (2024-2029) & (US$ Million)

    Table 36. Europe Myelodysplastic Syndrome Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029

    Table 37. Europe Myelodysplastic Syndrome Market Size by Country (2018-2023) & (US$ Million)

    Table 38. Europe Myelodysplastic Syndrome Market Size by Country (2024-2029) & (US$ Million)

    Table 39. Asia-Pacific Myelodysplastic Syndrome Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2029

    Table 40. Asia-Pacific Myelodysplastic Syndrome Market Size by Region (2018-2023) & (US$ Million)

    Table 41. Asia-Pacific Myelodysplastic Syndrome Market Size by Region (2024-2029) & (US$ Million)

    Table 42. Latin America Myelodysplastic Syndrome Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029

    Table 43. Latin America Myelodysplastic Syndrome Market Size by Country (2018-2023) & (US$ Million)

    Table 44. Latin America Myelodysplastic Syndrome Market Size by Country (2024-2029) & (US$ Million)

    Table 45. Middle East & Africa Myelodysplastic Syndrome Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029

    Table 46. Middle East & Africa Myelodysplastic Syndrome Market Size by Country (2018-2023) & (US$ Million)

    Table 47. Middle East & Africa Myelodysplastic Syndrome Market Size by Country (2024-2029) & (US$ Million)

    Table 48. Celgene Company Detail

    Table 49. Celgene Business Overview

    Table 50. Celgene Myelodysplastic Syndrome Product

    Table 51. Celgene Revenue in Myelodysplastic Syndrome Business (2018-2023) & (US$ Million)

    Table 52. Celgene Recent Development

    Table 53. Novartis Company Detail

    Table 54. Novartis Business Overview

    Table 55. Novartis Myelodysplastic Syndrome Product

    Table 56. Novartis Revenue in Myelodysplastic Syndrome Business (2018-2023) & (US$ Million)

    Table 57. Novartis Recent Development

    Table 58. Otsuka Company Detail

    Table 59. Otsuka Business Overview

    Table 60. Otsuka Myelodysplastic Syndrome Product

    Table 61. Otsuka Revenue in Myelodysplastic Syndrome Business (2018-2023) & (US$ Million)

    Table 62. Otsuka Recent Development

    Table 63. Actinium Pharmaceuticals Company Detail

    Table 64. Actinium Pharmaceuticals Business Overview

    Table 65. Actinium Pharmaceuticals Myelodysplastic Syndrome Product

    Table 66. Actinium Pharmaceuticals Revenue in Myelodysplastic Syndrome Business (2018-2023) & (US$ Million)

    Table 67. Actinium Pharmaceuticals Recent Development

    Table 68. Acceleron Pharma Company Detail

    Table 69. Acceleron Pharma Business Overview

    Table 70. Acceleron Pharma Myelodysplastic Syndrome Product

    Table 71. Acceleron Pharma Revenue in Myelodysplastic Syndrome Business (2018-2023) & (US$ Million)

    Table 72. Acceleron Pharma Recent Development

    Table 73. Bellicum Pharmaceuticals Company Detail

    Table 74. Bellicum Pharmaceuticals Business Overview

    Table 75. Bellicum Pharmaceuticals Myelodysplastic Syndrome Product

    Table 76. Bellicum Pharmaceuticals Revenue in Myelodysplastic Syndrome Business (2018-2023) & (US$ Million)

    Table 77. Bellicum Pharmaceuticals Recent Development

    Table 78. Cornerstone Pharmaceuticals Company Detail

    Table 79. Cornerstone Pharmaceuticals Business Overview

    Table 80. Cornerstone Pharmaceuticals Myelodysplastic Syndrome Product

    Table 81. Cornerstone Pharmaceuticals Revenue in Myelodysplastic Syndrome Business (2018-2023) & (US$ Million)

    Table 82. Cornerstone Pharmaceuticals Recent Development

    Table 83. CTI BioPharma Company Detail

    Table 84. CTI BioPharma Business Overview

    Table 85. CTI BioPharma Myelodysplastic Syndrome Product

    Table 86. CTI BioPharma Revenue in Myelodysplastic Syndrome Business (2018-2023) & (US$ Million)

    Table 87. CTI BioPharma Recent Development

    Table 88. Onconova Therapeutics Company Detail

    Table 89. Onconova Therapeutics Business Overview

    Table 90. Onconova Therapeutics Myelodysplastic Syndrome Product

    Table 91. Onconova Therapeutics Revenue in Myelodysplastic Syndrome Business (2018-2023) & (US$ Million)

    Table 92. Onconova Therapeutics Recent Development

    Table 93. Strategia Therapeutics Company Detail

    Table 94. Strategia Therapeutics Business Overview

    Table 95. Strategia Therapeutics Myelodysplastic Syndrome Product

    Table 96. Strategia Therapeutics Revenue in Myelodysplastic Syndrome Business (2018-2023) & (US$ Million)

    Table 97. Strategia Therapeutics Recent Development

    Table 98. KaloBios Pharmaceuticals Company Detail

    Table 99. KaloBios Pharmaceuticals Business Overview

    Table 100. KaloBios Pharmaceuticals Myelodysplastic Syndrome Product

    Table 101. KaloBios Pharmaceuticals Revenue in Myelodysplastic Syndrome Business (2018-2023) & (US$ Million)

    Table 102. KaloBios Pharmaceuticals Recent Development

    Table 103. Kiadis Pharma Company Detail

    Table 104. Kiadis Pharma Business Overview

    Table 105. Kiadis Pharma Myelodysplastic Syndrome Product

    Table 106. Kiadis Pharma Revenue in Myelodysplastic Syndrome Business (2018-2023) & (US$ Million)

    Table 107. Kiadis Pharma Recent Development

    Table 108. Mirati Therapeutics Company Detail

    Table 109. Mirati Therapeutics Business Overview

    Table 110. Mirati Therapeutics Myelodysplastic Syndrome Product

    Table 111. Mirati Therapeutics Revenue in Myelodysplastic Syndrome Business (2018-2023) & (US$ Million)

    Table 112. Mirati Therapeutics Recent Development

    Table 113. Astex Company Detail

    Table 114. Astex Business Overview

    Table 115. Astex Myelodysplastic Syndrome Product

    Table 116. Astex Revenue in Myelodysplastic Syndrome Business (2018-2023) & (US$ Million)

    Table 117. Astex Recent Development

    Table 118. Celator Pharmaceuticals Company Detail

    Table 119. Celator Pharmaceuticals Business Overview

    Table 120. Celator Pharmaceuticals Myelodysplastic Syndrome Product

    Table 121. Celator Pharmaceuticals Revenue in Myelodysplastic Syndrome Business (2018-2023) & (US$ Million)

    Table 122. Celator Pharmaceuticals Recent Development

    Table 123. Eli-lilly Company Detail

    Table 124. Eli-lilly Business Overview

    Table 125. Eli-lilly Myelodysplastic Syndrome Product

    Table 126. Eli-lilly Revenue in Myelodysplastic Syndrome Business (2018-2023) & (US$ Million)

    Table 127. Eli-lilly Recent Development

    Table 128. Sunesis Pharmaceuticals Company Detail

    Table 129. Sunesis Pharmaceuticals Business Overview

    Table 130. Sunesis Pharmaceuticals Myelodysplastic Syndrome Product

    Table 131. Sunesis Pharmaceuticals Revenue in Myelodysplastic Syndrome Business (2018-2023) & (US$ Million)

    Table 132. Sunesis Pharmaceuticals Recent Development

    Table 133. Targazyme Company Detail

    Table 134. Targazyme Business Overview

    Table 135. Targazyme Myelodysplastic Syndrome Product

    Table 136. Targazyme Revenue in Myelodysplastic Syndrome Business (2018-2023) & (US$ Million)

    Table 137. Targazyme Recent Development

    Table 138. Gamida Cell Company Detail

    Table 139. Gamida Cell Business Overview

    Table 140. Gamida Cell Myelodysplastic Syndrome Product

    Table 141. Gamida Cell Revenue in Myelodysplastic Syndrome Business (2018-2023) & (US$ Million)

    Table 142. Gamida Cell Recent Development

    Table 143. GlaxoSmithKline Company Detail

    Table 144. GlaxoSmithKline Business Overview

    Table 145. GlaxoSmithKline Myelodysplastic Syndrome Product

    Table 146. GlaxoSmithKline Revenue in Myelodysplastic Syndrome Business (2018-2023) & (US$ Million)

    Table 147. GlaxoSmithKline Recent Development

    Table 148. Sumitomo Dainippon Pharma Company Detail

    Table 149. Sumitomo Dainippon Pharma Business Overview

    Table 150. Sumitomo Dainippon Pharma Myelodysplastic Syndrome Product

    Table 151. Sumitomo Dainippon Pharma Revenue in Myelodysplastic Syndrome Business (2018-2023) & (US$ Million)

    Table 152. Sumitomo Dainippon Pharma Recent Development

    Table 153. TetraLogic Pharmaceuticals Company Detail

    Table 154. TetraLogic Pharmaceuticals Business Overview

    Table 155. TetraLogic Pharmaceuticals Myelodysplastic Syndrome Product

    Table 156. TetraLogic Pharmaceuticals Revenue in Myelodysplastic Syndrome Business (2018-2023) & (US$ Million)

    Table 157. TetraLogic Pharmaceuticals Recent Development

    Table 158. Research Programs/Design for This Report

    Table 159. Key Data Information from Secondary Sources

    Table 160. Key Data Information from Primary Sources

List of Figures

    Figure 1. Global Myelodysplastic Syndrome Market Size Comparison by Type (2023-2029) & (US$ Million)

    Figure 2. Global Myelodysplastic Syndrome Market Share by Type: 2022 VS 2029

    Figure 3. Alkylating Agents Features

    Figure 4. Cytotoxic Antibiotics Features

    Figure 5. Topoisomerase Inhibitors Features

    Figure 6. Others Features

    Figure 7. Global Myelodysplastic Syndrome Market Size Comparison by Application (2023-2029) & (US$ Million)

    Figure 8. Global Myelodysplastic Syndrome Market Share by Application: 2022 VS 2029

    Figure 9. Hospital Case Studies

    Figure 10. Clinic Case Studies

    Figure 11. Myelodysplastic Syndrome Report Years Considered

    Figure 12. Global Myelodysplastic Syndrome Market Size (US$ Million), Year-over-Year: 2018-2029

    Figure 13. Global Myelodysplastic Syndrome Market Size, (US$ Million), 2018 VS 2022 VS 2029

    Figure 14. Global Myelodysplastic Syndrome Market Share by Region: 2022 VS 2029

    Figure 15. Global Myelodysplastic Syndrome Market Share by Players in 2022

    Figure 16. Global Top Myelodysplastic Syndrome Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Myelodysplastic Syndrome as of 2022)

    Figure 17. The Top 10 and 5 Players Market Share by Myelodysplastic Syndrome Revenue in 2022

    Figure 18. North America Myelodysplastic Syndrome Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 19. North America Myelodysplastic Syndrome Market Share by Country (2018-2029)

    Figure 20. United States Myelodysplastic Syndrome Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 21. Canada Myelodysplastic Syndrome Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 22. Europe Myelodysplastic Syndrome Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 23. Europe Myelodysplastic Syndrome Market Share by Country (2018-2029)

    Figure 24. Germany Myelodysplastic Syndrome Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 25. France Myelodysplastic Syndrome Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 26. U.K. Myelodysplastic Syndrome Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 27. Italy Myelodysplastic Syndrome Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 28. Russia Myelodysplastic Syndrome Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 29. Nordic Countries Myelodysplastic Syndrome Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 30. Asia-Pacific Myelodysplastic Syndrome Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 31. Asia-Pacific Myelodysplastic Syndrome Market Share by Region (2018-2029)

    Figure 32. China Myelodysplastic Syndrome Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 33. Japan Myelodysplastic Syndrome Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 34. South Korea Myelodysplastic Syndrome Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 35. Southeast Asia Myelodysplastic Syndrome Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 36. India Myelodysplastic Syndrome Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 37. Australia Myelodysplastic Syndrome Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 38. Latin America Myelodysplastic Syndrome Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 39. Latin America Myelodysplastic Syndrome Market Share by Country (2018-2029)

    Figure 40. Mexico Myelodysplastic Syndrome Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 41. Brazil Myelodysplastic Syndrome Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 42. Middle East & Africa Myelodysplastic Syndrome Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 43. Middle East & Africa Myelodysplastic Syndrome Market Share by Country (2018-2029)

    Figure 44. Turkey Myelodysplastic Syndrome Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 45. Saudi Arabia Myelodysplastic Syndrome Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 46. Celgene Revenue Growth Rate in Myelodysplastic Syndrome Business (2018-2023)

    Figure 47. Novartis Revenue Growth Rate in Myelodysplastic Syndrome Business (2018-2023)

    Figure 48. Otsuka Revenue Growth Rate in Myelodysplastic Syndrome Business (2018-2023)

    Figure 49. Actinium Pharmaceuticals Revenue Growth Rate in Myelodysplastic Syndrome Business (2018-2023)

    Figure 50. Acceleron Pharma Revenue Growth Rate in Myelodysplastic Syndrome Business (2018-2023)

    Figure 51. Bellicum Pharmaceuticals Revenue Growth Rate in Myelodysplastic Syndrome Business (2018-2023)

    Figure 52. Cornerstone Pharmaceuticals Revenue Growth Rate in Myelodysplastic Syndrome Business (2018-2023)

    Figure 53. CTI BioPharma Revenue Growth Rate in Myelodysplastic Syndrome Business (2018-2023)

    Figure 54. Onconova Therapeutics Revenue Growth Rate in Myelodysplastic Syndrome Business (2018-2023)

    Figure 55. Strategia Therapeutics Revenue Growth Rate in Myelodysplastic Syndrome Business (2018-2023)

    Figure 56. KaloBios Pharmaceuticals Revenue Growth Rate in Myelodysplastic Syndrome Business (2018-2023)

    Figure 57. Kiadis Pharma Revenue Growth Rate in Myelodysplastic Syndrome Business (2018-2023)

    Figure 58. Mirati Therapeutics Revenue Growth Rate in Myelodysplastic Syndrome Business (2018-2023)

    Figure 59. Astex Revenue Growth Rate in Myelodysplastic Syndrome Business (2018-2023)

    Figure 60. Celator Pharmaceuticals Revenue Growth Rate in Myelodysplastic Syndrome Business (2018-2023)

    Figure 61. Eli-lilly Revenue Growth Rate in Myelodysplastic Syndrome Business (2018-2023)

    Figure 62. Sunesis Pharmaceuticals Revenue Growth Rate in Myelodysplastic Syndrome Business (2018-2023)

    Figure 63. Targazyme Revenue Growth Rate in Myelodysplastic Syndrome Business (2018-2023)

    Figure 64. Gamida Cell Revenue Growth Rate in Myelodysplastic Syndrome Business (2018-2023)

    Figure 65. GlaxoSmithKline Revenue Growth Rate in Myelodysplastic Syndrome Business (2018-2023)

    Figure 66. Sumitomo Dainippon Pharma Revenue Growth Rate in Myelodysplastic Syndrome Business (2018-2023)

    Figure 67. TetraLogic Pharmaceuticals Revenue Growth Rate in Myelodysplastic Syndrome Business (2018-2023)

    Figure 68. Bottom-up and Top-down Approaches for This Report

    Figure 69. Data Triangulation

    Figure 70. Key Executives Interviewed